Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
about
Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126.Downregulation of A20 increases the cytotoxicity of IFN-γ in hepatocellular carcinoma cellsCombination of sorafenib and Valproic acid synergistically induces cell apoptosis and inhibits hepatocellular carcinoma growth via down-regulating Notch3 and pAkt.Drug-based perturbation screen uncovers synergistic drug combinations in Burkitt lymphoma
P2860
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Single Agent and Synergistic A ...... b in Hepatocellular Carcinoma.
@en
type
label
Single Agent and Synergistic A ...... b in Hepatocellular Carcinoma.
@en
prefLabel
Single Agent and Synergistic A ...... b in Hepatocellular Carcinoma.
@en
P2093
P2860
P1476
Single Agent and Synergistic A ...... b in Hepatocellular Carcinoma.
@en
P2093
Adam M Burgoyne
Alok R Singh
Donald L Durden
Guillermo A Morales
Jason K Sicklick
Joseph R Garlich
Sadakatsu Ikeda
Shweta Joshi
P2860
P304
P356
10.1158/1535-7163.MCT-15-0976
P577
2016-08-05T00:00:00Z